A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma

Trial Profile

A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Pexidartinib (Primary) ; Vemurafenib
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Plexxikon
  • Most Recent Events

    • 28 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Sep 2013 New source identified and integrated (Vanderbilt-Ingram Cancer Center, VICCPHI1328).
    • 05 Sep 2013 Status changed from not yet recruiting to recruiting as reported by Vanderbilt-Ingram Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top